Todd Carter is a neuroscientists and the Chief Scientific Officer (CSO) of Voyager Therapeutics. Prior to joining Voyager, Carter served as the Senior Science Advisor to the Office of the Director of the Broad Institute of MIT and Harvard, where he focused on advancing innovative science concepts toward the clinic. Prior to that, he held research positions at BrainCells Inc. and Ambit Biosciences Inc. He led novel gene therapy development programs and supported the development of the TRACER™ platform, the identification of novel AAV capsids, and the execution of multiple successful industry partnerships.

Carter received a B.A. in genetics from Texas A&M University, a Ph.D. in genetics from Columbia University, and completed his postdoctoral training at the Salk Institute for Biomedical Research.